These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 25221952)
1. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells. Sako H; Fukuda K; Saikawa Y; Nakamura R; Takahashi T; Wada N; Kawakubo H; Takeuchi H; Ohmori T; Kitagawa Y PLoS One; 2014; 9(9):e107613. PubMed ID: 25221952 [TBL] [Abstract][Full Text] [Related]
2. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells. Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561 [TBL] [Abstract][Full Text] [Related]
3. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855 [TBL] [Abstract][Full Text] [Related]
4. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Weisberg E; Wright RD; Jiang J; Ray A; Moreno D; Manley PW; Fabbro D; Hall-Meyers E; Catley L; Podar K; Kung AL; Griffin JD Gastroenterology; 2006 Dec; 131(6):1734-42. PubMed ID: 17087936 [TBL] [Abstract][Full Text] [Related]
5. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo. Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595 [TBL] [Abstract][Full Text] [Related]
6. Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors. Lu X; Pang Y; Cao H; Liu X; Tu L; Shen Y; Jia X; Lee JC; Wang Y Cancer Res; 2021 May; 81(9):2481-2494. PubMed ID: 33727226 [TBL] [Abstract][Full Text] [Related]
7. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Edris B; Willingham SB; Weiskopf K; Volkmer AK; Volkmer JP; Mühlenberg T; Montgomery KD; Contreras-Trujillo H; Czechowicz A; Fletcher JA; West RB; Weissman IL; van de Rijn M Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3501-6. PubMed ID: 23382202 [TBL] [Abstract][Full Text] [Related]
8. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor. Gao X; Xue A; Fang Y; Shu P; Ling J; Hou Y; Shen K; Qin J; Sun Y; Qin X Oncotarget; 2016 Mar; 7(12):14300-9. PubMed ID: 26893362 [TBL] [Abstract][Full Text] [Related]
9. SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling. Sugase T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hiramatsu K; Nishida T; Hirota S; Saito Y; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Hanasaki K; Kishimoto T; Mori M; Doki Y; Naka T Gastric Cancer; 2018 Nov; 21(6):968-976. PubMed ID: 29623544 [TBL] [Abstract][Full Text] [Related]